Anzeige
Mehr »
Login
Montag, 29.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1121A | ISIN: US45781A1079 | Ticker-Symbol:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INSTITUTE OF BIOMEDICAL RESEARCH CORP Chart 1 Jahr
5-Tage-Chart
INSTITUTE OF BIOMEDICAL RESEARCH CORP 5-Tage-Chart
ACCESSWIRE
358 Leser
Artikel bewerten:
(2)

Institute of BioMedical Research Corp.: MRES: M2Bio Sciences Marks Milestone Expansion with Launch of Los Angeles Office

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 14, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to provide the following update:

M2Bio Sciences Food & Beverage strategically expands its presence by opening offices in Los Angeles, California. This move aims to broaden the distribution of Liviana and Medspresso products within the United States, aligning with the company's global commitment to providing healthy and trusted food products backed by evidence-based clinical science.

M2Bio is set to collaborate with Rand Capital Coffee within the premises. Rand Capital, founded in 2010, oversees and manages over 70 premium coffee cafes across Southern Africa. The offices are at 1515 Palisades Drive, Pacific Palisades, CA.

Michael Sachar, CEO of M2Bio Sciences Food and Beverage, expressed excitement about the expansion, stating, "We are ecstatic about opening the M2Bio Sciences Food and Beverage offices in Los Angeles. Having a solid base in California allows us to gain a foothold on the West Coast as our rollout for North American distribution for 2024 gains momentum. We have seen phenomenal growth in the food division and are excited to share our premium health-centric products with new partners and consumers."

About Institute of Biomedical Research Corp./ DBA M2Bio Sciences

Institute of Biomedical Research Corp is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx, Medspresso, Liviana brands as well as artificial intelligence-powered nutrition products and solutions under the M2Biome brand. In addition, our research and clinical trials with psilocybin are aimed at new therapies to help patients suffering from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies such as artificial intelligence.

The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES."

Publicly traded Company (OTC Pink: MRES)

www.m2bio.co

Forward-Looking Statements

Safe Harbour Statement - Besides historical information, this press release may contain forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team concerning the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance, involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments concerning litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.

CONTACT:

Jeff Robinson
M2Bio Sciences
+27 72 333 2148
Email us here

Visit us on social media:

Facebook

Twitter

LinkedIn

Instagram

YouTube

SOURCE: Institute of BioMedical Research Corp.

View source version on accesswire.com:
https://www.accesswire.com/803069/mres-m2bio-sciences-marks-milestone-expansion-with-launch-of-los-angeles-office

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2023 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.